cyrilzakka/clinical-trials huggingface dataset:
Impact of Family Psychoeducation on Psychosis

There is currently no clear involvement of families/caregivers in the care for postpartum mothers that develop postpartum psychosis. The lack of knowledge on causes of postpartum psychosis may influence the nature of perceived social support that mothers receive from caregivers. It is hoped that the provision of a culturally adapted version of family psychoeducation will bridge the knowledge gap and provide the much needed information. We therefore hypothesized that the involvement of a family member of a postpartum mother with a psychotic illness in a weekly session of family psychoeducation.

Postpartum psychosis causes distress to the mother, baby, spouse and other primary caregivers. This is especially true for Uganda where cultural beliefs for the causation of the illness place blame on supposedly the postpartum mother's promiscuity during pregnancy (COX, 1979). Cultural perceptions on the causes of postpartum psychosis may affect the nature of social support the mothers perceive from their families when they develop the illness. Other perceptions regarding postpartum psychosis in Uganda lay blame on supernatural causes like witchcraft.

Family psychoeducation which sets out to inform families of the nature of the illness is called for so as to demystify the illness.

Eligibility Criteria:
Inclusion Criteria:

* Postpartum mothers with a psychiatric illness in the current postpartum period.
* Must have been admitted to the mental health facility for the current episode.

Exclusion Criteria:

* Mothers residing out of a radius of 50 km away from the health facility.
* Mothers that do not have caregivers.
* Mothers who are not fluent in the language in which the study will be conducted.
Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy

It is considered that whether or not the accompanying invasive cancer classified through MRI images of breast cancer patients identified as Ductal Carcinoma in situ (DCIS) through preoperative tissue biopsy is significantly consistent with the postoperative stage.

Therefore, this study intend to evaluate the effectiveness as a diagnostic tool that can help determine the axillary lymph node surgery by predicting the possibility of post-operative up-staging using magnetic resonance imagings of breast cancer patients who have been identified as ductal carcinoma in situ and are scheduled for surgery.

1. To date, there is no significant research data on the value of the Apparent Diffusion Coefficient (ADC) that can distinguish between pure Ductal Carcinoma in situ (pure DCIS) and invasive cancer (DCIS-IC), from June 2019 to 2020 1 Of the 144 patients who obtained Diffusion Weighted images (b=0,800,1200) with 3.0-T MRI equipment and diagnosed with ductal carcinoma in situ on the biopsy, among 144 patients who did not undergo preoperative chemotherapy using a CAD program, the 3-dimensional Apparent Diffusion Coefficient value of the tumor is measured and compared with whether or not there is invasive cancer after surgery, and the optimal Apparent Diffusion Coefficient reference value that can predict the invasive cancer will be retrospectively derived.
2. Scheduled MRI tests will be performed on patients enrolled from July 2020, and will be performed using the standard protocols (3T, contrast enhancement and diffuse enhancement images DWI b0,800,1200). Among the MRI images taken, the range of lesions is evaluated in contrast-enhanced T1-highlighted images, and the Apparent Diffusion Coefficient values of the lesions are three-dimensionally mapped using a CAD program and histogram analysis on diffused images. The ADC reference value derived from the retrospective analysis is used to predict prospectively for invasive cancer in all lesions.
3. Mastectomy is performed according to the existing surgical method. Axillary lymph node surgery is determined according to the existing decision method (tumor location, size, range, histological grade, etc.).

Eligibility Criteria:
Inclusion Criteria:

* Adult over 19 years-old
* Breast Ductal Carcinoma in-situ patients who diagnosed preoperative tissue biopsy
* A person who understands this study and agrees with willingness to participate

Exclusion Criteria:

* Ductal Carcinoma in-situ which diagnosed excisional biopsy
* When there is no lesion that can be discriminated from magnetic resonance imaging
* Neoadjuvant chemotherapy patients
* Patients who have complication (hematoma, abscess etc.) after preoperative biopsy
COVID19-OR (SARS-CoV-2): Observation,Risk & Recovery

A novel coronavirus, designated corona virus disease 2019 (COVID-19) has resulted in a Pandemic at the time of writing (27th April) the reported number of confirmed cases exceeding 3 million and over 200000 associated deaths.

The burden on global critical care has been considerable. As of 24th April there have been 8752 UK critical care admissions with services under considerable strain, and a mortality rate over 50%. Survivors of critical illness will require significant input.

This study will perform mixed methods to provide rich data on risk stratification and recovery from critical illness. Recovery from a novel disease requires documenting and the study reports physical and psychological changes following hospital discharge in survivors. In addition qualitative interviews are being conducted with patients who have survived and been discharged from critical care along with their relatives and treating professionals, to better understand their needs during recovery.


Eligibility Criteria:
Inclusion Criteria:

1. Adults ≥18 years admitted to ICU with SARS-CoV-2 and survived
2. Relatives or friends and professionals involved in the care of these patients.

Exclusion Criteria:

1. Patients \<18 years;
2. Patients with a negative test for SARS-CoV-2 or patients not tested due to absence of symptoms;
Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain

The aim of the study was to evaluate the safety and effectiveness of Platelet Derived Growth Factor (PDGF) mixed with b tricalcium phosphate (BTCP) for the treatment of advanced periodontal osseous defects at 6 months of healing.

This triple blind, prospective and parallel arm trial was conducted in subjects requiring surgical treatment of a periodontal osseous defect.

Eligibility Criteria:
Inclusion Criteria:

* probing depth of 7mm or greater at baseline
* following debridement, 4mm or greater vertical bone defect depth with at least one intact bony wall
* sufficient keratinized tissue to allow complete tissue coverage of the defect
* a radiographic base of the defect at least 3mm coronal to the apex of the tooth
* no evidence of localized aggressive periodontitis
* smoke less than 1 pack of cigarettes per day

Exclusion Criteria:

* failure to maintain adequate oral hygiene
* pregnant women or women intending to become pregnant
* history of oral cancer within last 6 months or HIV
* history within last year of periodontal surgery on study tooth
* study tooth mobility greater than 2
* study tooth exhibiting a class 3 furcation defect
* signs of untreated acute infection at the surgical site, apical pathology, root fracture, severe root irregularities, cemental pearls, cementoenamel junction (CEJ) projections not easily removed, untreated carious lesions at the CEJ or on the root surface, subgingival restorations or restorations with open margins at or below CEJ
* history within 6 months of weekly or more frequent use of smokeless chewing tobacco, pipe or cigar smoking, or more than 20 cigarettes a day
* allergy to yeast derived products
* investigational therapy within 30 days of surgery
Genicular Artery Embolization (GAE) for Osteoarthritic Knee Pain

The objective of this investigation is to evaluate the safety of the geniculate artery embolization (GAE) procedure with HydroPearl® Microspheres in 30 patients with knee pain caused by osteoarthritis with 24 months follow-up. The GAE procedure is an arterial embolization procedure that blocks abnormal blood vessels caused be knee arthritis in order to evaluate the effect on knee pain.


Eligibility Criteria:
Inclusion Criteria:

1. Provide informed consent
2. Age ≥ 40 years
3. Moderate to severe knee pain (VAS \>40 mm)
4. Pain refractory to 3 months of conservative treatments, including at least one of the following:

   * a. Anti-inflammatory medications
   * b. Physical therapy
   * c. Intra-articular injections
5. Kellgren-Lawrence radiographic grade 1, 2, or 3 disease
6. MRI features of active synovitis (synovial thickening and/or enhancement on MRI).
7. Ineligibility or refusal of surgical management.
8. Local knee tenderness

Exclusion Criteria:

1. Rheumatoid or infectious arthritis
2. Advanced lower extremity atherosclerosis that would limit selective angiography
3. Local knee infection
4. Prior knee surgery (excluding arthroscopic/meniscal interventions)
5. Uncorrectable coagulopathy (INR\>1.8, platelets\<50,000/µL)
6. Iodine allergy resulting in anaphylaxis
7. Chronic renal insufficiency (serum creatinine \>2 mg/dL)
8. Life expectancy less than 6 months
Pilot Study of Cognitive Assessment in Welsh Speakers

19% of Wales' population speaks Welsh. Under the Welsh Language Act 1993, every public body providing services to the public in Wales has to prepare a scheme setting out how it will provide those services in Welsh.

Diagnosing dementia requires a comprehensive assessment, an essential component of which is a cognitive assessment tool, which takes the form of a questionnaire. In clinical practice, this is currently only available through the medium of English.

The investigators objective is to measure the difference between Cognitive Assessment scores (using the Montreal cognitive assessment (MoCA)), when done in English and Welsh, in those who are cognitively impaired and whose first language is Welsh. The investigators predict that there will be a significant difference in scores in favour of the Welsh-medium tests, thus proving that the current mode of administering the test is prejudiced against patients whose first language is Welsh.

If the investigators predictions are correct, then the investigators would seek to introduce a validated Welsh-language cognitive assessment tool to the domain of the Welsh NHS.


Eligibility Criteria:
Inclusion Criteria:

* Welsh Speakers - self-identify as first-language Welsh
* Diagnosis of Dementia - recorded in patient's case notes

Exclusion Criteria:

* Refusal
* Intercurrent illness
* Blind/any other disability which may prevent participant from fully completing Cognitive Assessment
Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection

Bronchopulmonary cancer, with 39 000 new cases and 30 000 deaths per year, is a main issue in public health in France. It is the leading cause of cancer death in France. A lot of progress in medical care has been made, but surgery remains the most effective treatment, when it is still possible. The goal is to detect and manage the lung cancer as early as possible. Alongside screening strategies by annual thoracic scanner, new approaches with innovative technologies open up for cancer detection and therapeutic follow-up.

The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The volatolomic analysis can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases.

The composition of VOC in exhaled air and sweat is altered in patients with lung cancer. The VOC analysis and their variation could be used particularly in the follow-up of patients treated for lung cancer.

The purpose of this clinical research is to identify the VOCs related to lung cancers by comparing the VOC profiles in exhaled air and in sweat from patients diagnosed with localized lung cancer before and after resection surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patient aged ≥ 18 years old
* Patient with non-small cell lung cancer
* Operable grade I or II
* No specific treatment before surgery (radiotherapy, chemotherapy or targeted therapy)
* Patient with healthcare insurance

Non Inclusion Criteria:

* Treatment with radiotherapy, chemotherapy, or neoadjuvant cancer targeted therapy before thoracic surgery
* Patient with oxygen therapy or invasive ventilation
* Patient unable to perform a slow vital capacity
* Dermatological therapy interfering with sweat collection (psoriasis, irritant dermatitis, for instance)
* Pregnant women
* Patient deprived of liberty by judicial or administrative decision
Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia

The purpose of this study is to evaluate the cognitive processes of participants with schizophrenia, participants with nervous system and mental disorders, and healthy volunteers.

Participants in this study will undergo cognitive tests of attention, memory, attention. Participants with attention deficit hyperactivity disorder (ADHD), traumatic brain injury (TBI), bipolar disorder, and Alzheimer's disease (AD) will be compared with participants with schizophrenia. A group of healthy adults and children will undergo cognitive tests to further delineate the degree of impairment in schizophrenia and neurological disorder participants.

In this study, we propose to administer cognitive tests to schizophrenic patients and to neurologic patients who will serve as contrast groups for neuropsychological studies of patients with schizophrenia. These include studies of Alzheimers disease to dissociate size and organization of lexicon and ADHD to understand error patterns on CPT-type tests of attention and vigilance. However, the majority of studies will examine schizophrenia in relation to normal controls.

In addition, we propose to obtain test results from a local sample of normal subjects of varying ages and educational backgrounds to further delineate degree of impairment in these clinical groups. As well as assessing adults we wish to assess normal children. In particular, we wish to identify in children the size of their lexicon and their degree of semantic organization within their lexicon.

Eligibility Criteria:
INCLUSION CRITERIA

English-speaking adults between ages 21 to 65, in good health and free from significant substance abuse.

Children between ages 4 to 20 must not have a history of special education, using psychotropic medication in long-term counseling or with a history of seizures, head injury or CNS infections.

Normal controls will be recruited and screened for exclusionary morbidity by interview (e.g., no history of contact with mental health professionals, no history of diagnosable alcohol and/or substance abuse).

Normal controls will be recruited from building employees, local universities, from NIMH rosters, and the general public.

EXCLUSION CRITERIA

Excluded are adults with histories of dementing illness, movement disorder, affective disorders, developmental and/or acquired brain injury. Diagnoses will be made by review of medical records, interview, examination, and in the case of psychiatric diagnoses, a structured interview by SCID.

Advertisement will make clear that the subjects will be asked questions about family psychiatric history and their own history or psychiatric disorder, substance abuse, and neurological disease. Only if the subject answers these negatively will he or she participate in this study.
Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML and determine the best dosage.

Eligibility Criteria:
Inclusion Criteria:

* Patients with CD123+ Refractory or Relapsed AML
* To be aged 3 to 80 years
* Expression of CD123 in Blast ≥90%
* ECOG score ≤2
* Voluntary participation in the clinical trials and sign the informed consent.

Exclusion Criteria:

* Intracranial hypertension or unconsciousness
* Respiratory failure
* CD19 negative
* Disseminated intravascular coagulation
* ALT /AST\>3 x normal value; Creatinine\> 1.5 x normal value; Bilirubin \>2.0 x -normal value
* Hematosepsis or Uncontrolled active infection
* Uncontrolled diabetes
* Abalienation;
* Patients in pregnancy or breast-feeding period
* Previously treatment with any gene therapy products
* Any uncontrolled medical disorders that the researchers consider are not eligible to participate the clinical trial
Safety and Efficacy of Facial Cleanser

This study is conducted to evaluate the safety and effectiveness of facial cleanser X containing combination of olive oil, virgin coconut oil, butylene glycol and hyaluronic acid on skin hydration and skin elasticity. The study duration is 5 weeks and the skin assessment will be carried out at baseline, week 3 and week 5.The main questions this study aims to answer are:

1. The effect of product on skin hydration.
2. The effect of product on skin elasticity.
3. To observe any adverse effect occurrence with the usage of the product.


Eligibility Criteria:
Inclusion Criteria:

* Malaysia citizen
* Male and female (age 35-55 years old)

Exclusion Criteria:

* Participants who have acne which require medical treatment.
* Participants taking isotretinoin
* Participants who had undergo any cosmetic procedures such as laser \& light treatment, botulinum toxin A injections and chemical peeling for the past 3 months
* Participants who are immunocompromised
* Participants with history of facial surgery
Establishing the Vitamin D Requirements During Lactation

The purpose of this study is to determine the effectiveness and safety of maternal and infant vitamin D supplementation as a function of ethnicity and latitude in the prevention of vitamin D deficiency in the breastfeeding mother-infant pair. The findings of this study will generate important new information for health care professionals and policy makers with regard to vitamin D requirements and the potential benefit to both mother and infant

Mothers from two study sites at different latitudes will be randomized to receive 1 of 3 treatment regimes of vitD3. Mothers, lactating or nonlactating controls will be randomized to either Group A: standard treatment(400 IU D3/d), Group B: (2,400 IU D3/d), or Group C: (6,400 IU D3/d. Infants of mothers randomized to Group A will receive 400 IU D3/d (recommended practice) and infants of mothers assigned to Groups B or C will receive placebo. On 2/5/2009, the protocol was amended and the Group B arm was dropped; infants of active subjects randomized to Group B as of 2/5/2009 were put on open label treatment (400 IU D3/d) through study completion. Newly enrolled subjects after this date were randomized to Group A or Group C only.

By measuring an array of indicators,calcium homeostasis and skeletal remodeling in the postpartum mother and the breastfeeding infant will be monitored. Through this study, the prevalence of vitD deficiency in the breastfeeding dyad and the utility of maternal therapeutic intervention with VitD3 will be assessed.

Eligibility Criteria:
Inclusion Criteria:

* Mother plans to breastfeed exclusively for at least six months
* Mother is in good health
* Infant is 35 weeks' gestation or greater
* Breastfeeding infant is in good health ( Level I nursery; or Level II nursery but not requiring oxygen therapy or parenteral nutrition beyond first 72 hours).

Exclusion Criteria:

* Mother does not plan to breastfeed exclusively for the first six months (plans to use formula for infant's feedings during the first six months
* Infant has been admitted to Neonatal Intensive Care unit requiring oxygen therapy or parental nutrition beyond the first 72 hours
* Infant is less than 35 weeks' gestation
* Infant has been diagnosed with a congenital anomaly or abnormal chromosomal pattern
* Mother has a history of endocrine dysfunction involving parathyroid gland, diabetes, or calcium abnormalities related to renal disease such that calcium parameters are abnormal
* Mother has history of hypercalciuria
Telecommunication Via Cell Phones During Post-Operative Treatment After Lung Transplantation

In an investigation should be evaluated in contrast to a control group with standard post-treatment therapy (using home spirometry) after lung transplantation if transfer of home spirometry recordings to the transplant center via cell phones will lead to less complications, cost savings and bigger constancy of therapy.

Home spirometry is used as a standard of care in lung transplant recipients in many centers worldwide. In case of deteriorating lung function response until therapy depends on patients efforts to reach the transplant center and the contactability of the transplant center.

Therefore transfer of home spirometry recordings to the transplant center via cell phones will lead to less complications, cost savings and bigger constancy of therapy compared to the home spirometry alone.

Eligibility Criteria:
Inclusion Criteria:

* Patients after lung transplantation (single and double lung transplantation incl. combined organ transplantation) before hospital discharge

Exclusion Criteria:

* Dependency on long term care
* Restricted ability to communicate